密爾克衞(603713.SH):君聯茂林持股比例減少1.01%
格隆匯6月4日丨密爾克衞(603713.SH)公佈,公司於2021年6月4日接到持股5%以上股東北京君聯茂林股權投資合夥企業(有限合夥)(以下簡稱“君聯茂林”)的通知,君聯茂林於2021年1月26日至2021年6月4日期間通過上海證券交易所集中競價方式累計減持公司股份69.75萬股;2021年3月17日,公司完成非公開發行股票新增股份登記,公司總股本由1.55億股變更為1.64億股,君聯茂林持有公司股份佔總股本比例被動減少0.57%,股份變動比例累計已達到1.01%。本次權益變動後,信息披露義務人持有公司股份比例由9.83%減少至8.82%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.